Trial Search Results

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Target PharmaSolutions, Inc.

Stanford Investigator(s):


Inclusion Criteria:

   1. Male or female patients, age ≥18 years

   2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC
   cholangiocarcinoma may be included; patients who are candidates for surgical and
   non-surgical treatment, as well as those being followed without specific HCC therapy
   may be included)

Exclusion Criteria:

1. Inability to provide written informed consent

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pranali Suryavanshi